388 related articles for article (PubMed ID: 31184718)
21. CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma.
Jacobson CA
J Clin Oncol; 2019 Feb; 37(4):328-335. PubMed ID: 30557517
[TBL] [Abstract][Full Text] [Related]
22. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
Nakazawa Y
Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
[TBL] [Abstract][Full Text] [Related]
23. CAR T-cells: A John von Neumann legacy?
Quesnel B
Curr Res Transl Med; 2018 May; 66(2):35-36. PubMed ID: 29685844
[No Abstract] [Full Text] [Related]
24. Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy.
Gabelli M; Oporto-Espuelas M; Burridge S; Chu J; Farish S; Hedges E; Ware K; Williams L; Young L; Alajangi R; Ancliff P; Bartram J; Bonney D; Chenchara L; Chiesa R; Cugno C; Hodby K; Jalowiec KA; Lazareva A; Lucchini G; Mirci-Danicar OC; Mullanfiroze K; Pavasovic V; Rao A; Rao K; Riley L; Samarasinghe S; Shenton G; Silva J; Vora A; Hough R; Amrolia PJ; Ghorashian S
Blood Adv; 2024 Apr; 8(8):1959-1963. PubMed ID: 37820111
[No Abstract] [Full Text] [Related]
25. Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers.
Prasad V
Nat Rev Clin Oncol; 2018 Jan; 15(1):11-12. PubMed ID: 28975930
[No Abstract] [Full Text] [Related]
26. Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience.
Seitter SJ; McClelland PH; Ahlman MA; Goff SL; Yang JC; McIntyre L; Rosenberg SA; Kochenderfer JN; Brudno JN
Leuk Lymphoma; 2022 Oct; 63(10):2469-2473. PubMed ID: 35679521
[No Abstract] [Full Text] [Related]
27. CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.
Cohen AD
Clin Adv Hematol Oncol; 2018 Dec; 16(12):804-806. PubMed ID: 30843888
[No Abstract] [Full Text] [Related]
28. CAR T-Cell Therapy in Autoimmune Disease.
Howard JF; Vu T; Mozaffar T
N Engl J Med; 2024 May; 390(17):1629-1631. PubMed ID: 38692299
[No Abstract] [Full Text] [Related]
29. Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Tan BJ; Chan LL; Tan EK
Neurology; 2023 Apr; 100(14):688. PubMed ID: 37012060
[No Abstract] [Full Text] [Related]
30. CAR T-Cell Therapy in Autoimmune Disease.
Merkt W; Lorenz HM; Schmitt M
N Engl J Med; 2024 May; 390(17):1628-1629. PubMed ID: 38692297
[No Abstract] [Full Text] [Related]
31. CAR T-Cell Therapy in Autoimmune Disease.
De Benedetti F; Diomedi Camassei F; Locatelli F
N Engl J Med; 2024 May; 390(17):1629. PubMed ID: 38692298
[No Abstract] [Full Text] [Related]
32. Celyad's novel CAR T-cell therapy for solid malignancies.
Lonez C; Hendlisz A; Shaza L; Aftimos P; Vouche M; Donckier V; Machiels JH; Van Den Eynde M; Canon JL; Carrasco J; Odunsi K; Sahebjam S; Rottey S; Braun N; Verma B; Gilham DE; Lehmann FF
Curr Res Transl Med; 2018 May; 66(2):53-56. PubMed ID: 29625833
[TBL] [Abstract][Full Text] [Related]
33. Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Karschnia P; Rejeski K; Subklewe M; von Baumgarten L
Neurology; 2023 Apr; 100(14):687-688. PubMed ID: 37012062
[No Abstract] [Full Text] [Related]
34. A New Frontier: CD19 Chimeric Antigen Receptor T-Cell Therapy.
Alcocer Alkureishi L; Hageman JR
Pediatr Ann; 2024 May; 53(5):e157-e158. PubMed ID: 38700917
[No Abstract] [Full Text] [Related]
35. CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications.
Köhl U; Arsenieva S; Holzinger A; Abken H
Hum Gene Ther; 2018 May; 29(5):559-568. PubMed ID: 29620951
[TBL] [Abstract][Full Text] [Related]
36. Upsetting the apple CAR-T (chimeric antigen receptor T-cell therapy) - sustainability mandates USA innovation.
Pantin J; Battiwalla M
Br J Haematol; 2020 Sep; 190(6):851-853. PubMed ID: 32358811
[TBL] [Abstract][Full Text] [Related]
37. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
Liu X; Zhao Y
Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
[TBL] [Abstract][Full Text] [Related]
38. Stuttering as the first sign of CAR-T-cell-related encephalopathy syndrome (CRES).
Gonzalez Castro LN; Dietrich J; Forst DA
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1917-1918. PubMed ID: 30539279
[No Abstract] [Full Text] [Related]
39. CD19-Targeting CAR T-Cell Therapy for Antisynthetase Syndrome.
Lundberg IE; Galindo-Feria AS; Horuluoglu B
JAMA; 2023 Jun; 329(24):2130-2131. PubMed ID: 37367988
[No Abstract] [Full Text] [Related]
40. Balancing the risks and benefits of CAR T-cell therapy.
The Lancet Haematology
Lancet Haematol; 2024 Mar; 11(3):e169. PubMed ID: 38423693
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
